Financial Results for the First Nine Months of Fiscal Year Ending December 2018

I	Summary	Information	P.1
	1	Financial Results	P.1
	2	Financial Conditions	P.1
Π	Financial F	Results for the First Nine Months of FY2018	P.2
	1	Statement of Income	P.2
	2	Sales of Products	P.4
	3	Balance Sheet	P.5
	4	Capital Expenditures	P.6
	5	Depreciation/Amortization	P.6
	6	Research and Development	P.6
Ш	Financial F	Forecasts for the FY2018	P.7
	1	Statement of Income	P.7
	2	Sales of Products	P.9
	3	Capital Expenditures	P.10
	4	Depreciation/Amortization	P.10
	5	Dividends	P.10
【In	nportant no	tes on forward-looking statements】	P.10

% This material is prepared based on Japan GAAP.

times Amounts are rounded down to the nearest million yen.

October 31, 2018



I Summary Information

① Financial Results

The forecasts for the FY2018 have been changed from the previous forecasts announced at the first six months of FY2018 financial results announcement on July 30, 2018.

(Millions of Yen)	FY2017 First nine months A	FY2018 First nine months	Change _{B-A}	Change (%) (B-A)/A	FY2017 Full year	FY2018 revised forecast C	Progress ratio (%) <i>B/C</i>
Net sales	45,726	45,543	(182)	(0.4)	64,135	62,000	73.5
Operating income	3,660	3,044	(616)	(16.8)	6,281	4,100	74.2
Ordinary income	3,735	3,134	(600)	(16.1)	6,403	4,200	74.6
Net income	2,771	2,248	(523)	(18.9)	4,718	3,000	75.0
(Reference)							
R&D expenses	3,516	3,101	(415)	(11.8)	4,608	4,400	70.5
Earnings per share (EPS)	(¥) 98.83	80.14	(18.69)		168.22	106.93	
Return on equity (ROE)	(%) 3.3	2.6	(0.7)		5.5	_	
Ratio of ordinary income to total assets	(%) 3.8	3.0	(0.8)		6.3	_	
Ratio of operating income to net sales	(%) 8.0	6.7	(1.3)		9.8	_	
Return on assets (ROA)	(%) 2.8	2.1	(0.7)		4.6	_	

(Cautionary Note Regarding FY2018 Forecasts)

In August 2018, Japan Tobacco Inc. (JT) signed a non-binding letter of intent (LOI) for initiating a discussion with Gilead Sciences, Inc. (Gilead) to terminate the license agreements for six anti-HIV drugs ("Viread Tablets" "Emtriva Capsules" "Truvada Combination Tablets" "Stribild Combination Tablets" "Genvoya Combination Tablets" and "Descovy Combination Tablets"). The anti-HIV drugs were developed by Gilead, and have been exclusively licensed to JT to develop and commercialize in Japan.


Torii and JT signed a non-binding LOI for initiating a discussion to terminate the license agreements by which JT grants Torii the exclusive rights to market the anti-HIV drugs in Japan.

The effect of the LOI on the business performance of Torii has not been incorporated in the forecasts for the FY2018. Torii will make a further announcement regarding this subject when appropriate.



FY2017 70 FY2018 62 60 50 41 36 40 30 30 20 Forecast 10 0 First nine months Full year

Operating income (0.1 billion yen)



② Financial Conditions

(Millions of Yen)		December 31, 2017 <i>A</i>	September 30, 2018 B	Change _{B-A}	Change (%) (B-A)/A
Total assets		104,741	104,754	12	0.0
Total equity		87,119	88,184	1,065	1.2
Equity ratio	(%)	83.2	84.2	1.0	
Book value per share (BPS)	(¥)	3,105.68	3,142.16	36.48	

I Financial Results for the First Nine Months of FY2018

① Statement of Income


(Millions of Yen)	FY2017	FY2018	Change	Change
	First nine months	First nine months	Change	(%)
Net color		<u>B</u>	<i>B-A</i>	(B-A)/A
Net sales	45,726	45,543	(182)	(0.4)
Sales of products	44,930	44,921	(8)	(0.0)
Renal disease and hemodialysis	17,995	16,579	(1,415)	(7.9)
Skin disease	7,235	6,744	(490)	(6.8)
Allergens	1,437	2,374	937	65.2
HIV infection	14,043	15,293	1,250	8.9
Other	4,218	3,928	(290)	(6.9)
Other sales	795	622	(173)	(21.7)
Cost of sales	22,602	23,547	945	4.2
Cost of products sold	22,561	23,507	945	4.2
Other cost	40	40	(0)	(0.8)
Gross profit	23,123	21,996	(1,127)	(4.9)
Selling, general and	10.462	10.052		
administrative expenses	19,463	18,952	(511)	(2.6)
R&D expenses	3,516	3,101	(415)	(11.8)
Others	15,946	15,850	(95)	(0.6)
Operating income	3,660	3,044	(616)	(16.8)
Non-operating income	86	94	7	
Non-operating expenses	12	4	(7)	_
Ordinary income	3,735	3,134	(600)	(16.1)
Extraordinary loss	20	24	3	
Income before income taxes	3,714	3,109	(604)	(16.3)
Income taxes	942	861	(81)	
Net income	2,771	2,248	(523)	(18.9)

(Reference) Ratio to net sales


(%)	FY2017 First nine months	FY2018 First nine months B	Change <i>B-A</i>
Cost of sales	49.4	51.7	2.3
SG&A	42.6	41.6	(1.0)
R&D expenses	7.7	6.8	(0.9)
Operating income	8.0	6.7	(1.3)
Ordinary income	8.2	6.9	(1.3)
Net income	6.1	4.9	(1.2)

[Factors in increase/decrease compared with the same term of the last fiscal year]

Net Sales (¥45,543 million : Decrease ¥182 million year-on-year)



Operating income (¥3,044 million : Decrease ¥616 million year-on-year)



Ordinary income (¥3,134 million : Decrease ¥600 million year-on-year)

Special remarks: None

Net income (¥2,248 million : Decrease ¥523 million year-on-year)

Special remarks: None

② Sales of Products

(2) Sales of Products	FY2017	FY2018	Charmen	Change	
(Millions of Yen)	First nine months	First nine months B	Change <i>B-A</i>	(%) (B-A)/A	
Sales of Products	44,930	44,921	(8)	(0.0)	
REMITCH	9,828	9,043	(784)	(8.0)	
Oral anti-pruritus agent [Renal disease and hemodialysis]					
Descovy Antiviral agent for HIV [HIV infection]	6,035	8,827	2,792	46.3	
Genvoya	4,410	5,246	836	19.0	
Antiviral agent for HIV [HIV infection]	.,	-,			
Riona Agent for hyperphosphatemia [Renal disease and hemodialysis]	4,438	4,754	316	7.1	
ANTEBATE X Topical corticosteroid [Skin disease]	4,559	4,057	(502)	(11.0)	
BIO-THREE Viable bacterial preparations [Other]	1,824	1,923	98	5.4	
KAYEXALATE X Agent for hyperkalemia [Renal disease and hemodialysis]	1,540	1,430	(110)	(7.2)	
CEDARTOLEN X Japanese cedar pollinosis (Allergen Immuno [Allergens]	883 therapy)	1,260	376	42.7	
LOCOID X Topical corticosteroid [Skin disease]	1,030	1,133	103	10.1	
ZEFNART Topical antifungal agent [Skin disease]	1,107	1,117	9	0.8	
Truvada Antiviral agent for HIV [HIV infection]	3,372	1,086	(2,285)	(67.8)	
FUTHAN X Protease inhibitor [Renal disease and hemodialysis]	1,435	837	(598)	(41.7)	
MITICURE House dust mite allergy (Allergen Immunoth [Allergens]	295 nerapy)	741	446	151.0	
Magsent Tocolysis in threatened premature labor Eclampsia-suppressing and treatment [Other]	789	693	(95)	(12.1)	
URINORM X Uricosuric agent [Renal disease and hemodialysis]	752	513	(238)	(31.7)	
Others	2,627	2,253	(374)	(14.3)	

※ In-house products

(References) Sales and ratio of in-house products

(Millions of Yen)	FY2017	FY2018	Change	Change
	First nine months	First nine months	Change	(%)
	А	В	B-A	(B-A)/A
Sales of in-house products	11,659	11,176	(482)	(4.1)
Ratio of in-house	%) 26.0	24.0	(1 1)	
product sales	%) 26.0	24.9	(1.1)	_

③ Balance Sheet

(Millions of Yen)	December 31, 2017 <i>A</i>	September 30, 2018 <i>B</i>	Change ^{B-A}	Change (%) (B-A)/A	Component ratio (%) (September 30, 2018)
Current assets	83,980	80,773	(3,206)	(3.8)	77.1
Cash and deposits	6,458	3,720	(2,737)		
Deposits in the cash	9,836	6,951	(2,885)		
management system	9,030	0,951	(2,005)		
Notes and accounts	20 122	25 244	(2, 770)		
receivable-trade	29,123	25,344	(3,779)		
Short-term	24 057	22.245			
investment securities	24,957	32,345	7,387		
Inventories	10,126	9,895	(231)		
Others	3,478	2,517	(961)		
Noncurrent assets	20,761	23,980	3,219	15.5	22.9
Property, plant and equipment	5,540	5,333	(206)		
Intangible assets	817	738	(78)		
Investments and other assets	14,403	17,908	3,505		
Investment securities	7,478	11,790	4,311		
Long-term prepaid expenses	5,748	4,994	(753)		
Others	1,176	1,123	(53)		
Total assets	104,741	104,754	12	0.0	100.0
Current liabilities	15,868	14,712	(1,156)	(7.3)	14.0
Accounts payable-trade	8,242	7,644	(598)		
Income taxes payable	1,396	333	(1,062)		
Accrued employees' bonuses	684	1,368	683		
Others	5,544	5,365	(178)		
Long-term liabilities	1,753	1,857	103	5.9	1.8
otal liabilities	17,622	16,570	(1,052)	(6.0)	15.8
Shareholders' equity	86,364	87,301	937	1.1	83.4
Unrealized gain on	745	871	126	17.0	0.8
available-for-sale securities	745	0/1	120		
Subscription rights to shares	9	11	1	14.3	0.0
otal equity	87,119	88,184	1,065	1.2	84.2
Total liabilities and equity	104,741	104,754	12	0.0	100.0
<u>Major factors in increase/decrease</u> (Current assets) Short-term : Increase wit	th acquisition of deb	t securities and true	st beneficiary rig	hts	

investment securities

(Noncurrent assets)

Investment securities : Increase with acquisition of debt securities

④ Capital Expenditures

(Millions of Yen)	FY2017 First nine months <i>A</i>	FY2018 First nine months <i>B</i>	Change _{B-A}	Change (%) <i>(B-A)/A</i>
Capital expenditures	650	485	(165)	(25.4)
PP&E	506	353	(152)	(30.2)
Intangible assets	144	132	(12)	(8.5)

ſ	Descriptions of capital expenditures						
	PP&E	: Investment mainly in manufacturing facilities aiming to maintain and improve productivity					
	Intangible assets	: Investment in software aiming to streamline operations					

(5) Depreciation/Amortization

(Millions of Yen)	FY2017 First nine months A	FY2018 First nine months B B-A		Change (%) (B-A)/A	
Depreciation and amortization of intangible assets	889	769	(120)	(13.6)	
Amortization of long-term prepaid expenses	793	761	(32)	(4.1)	

6 Research and Development

Development		Formulation/		Developm	ent stage (domestic)		
code	Indication	Route of administration	Phase I	Phase II	Phase III	Application	Approval	Remarks
Renal disease and	hemodialysis							
JTT-751 [Riona® Tablets]	Iron-deficiency anemia	Oral			Phase III			•Licensing agreement signed with Keryx for development and commercialization of hyperphosphatemia drug in Japan •Co-development with JT(Additional indication) •Riona filed by JT has been approved as a treatment of hyperphosphatemia in January 2014, and is being promoted and distributed by Torii.
JTZ-951	Anemia associated with chronic kidney disease	Oral			Phase III			• JT's original compound • Licensing agreement signed with JT for development and commercialization
Skin disease								
JTE-052	Atopic dermatitis	Topical			PhaseⅢ			• JT's original compound • Licensing agreement signed with JT for development and commercialization
312-052	Atopic dermatitis in children	Topical			PhaseⅢ			• JT's original compound • Licensing agreement signed with JT for development and commercialization
Allergens								
TO-203 [MITICURE® House Dust Mite	House dust mite induced allergic	Sublingual		Phase	е П / Ш			Licensing agreement signed with ALK for providing exclusive development and sales rights in Jana

Hou	TICURE® ise Dust Mite lingual	House dust mite induced allergic asthma (Allergen Immunotherapy)	Sublingual tablet	Phase I / Ⅲ (Study completed※)	providing exclusive development and sales rights in Japan •In-house
Tab	letsJ				Examining the future development policy

Updates since the previous announcement on July 30, 2018

 \cdot JTE-052 for the indication of atopic dermatitis in children has entered into the clinical stage(Phase II) in Japan.

(Reference)

In October 2017, JT announced that the company signed an exclusive license agreement with EirGen Pharma Limited for the development and commercialization in Japan of calcifediol extended-release capsules (marketed by OPKO Health, Inc. in the U.S. under the brand name "RAYALDEE®") for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease, and Torii is expected to commercialize the product once it is approved.

Ⅲ Financial Forecasts for the FY2018

The forecasts for the FY2018 have been changed from the previous forecasts announced at the first six months of FY2018 financial results announcement on July 30, 2018.

① Statement of Income

(Millions of Yen)	FY2018 previous forecast <i>A</i>	FY2018 revised forecast B	Change _{B-A}	FY2017 c	Change ^{B-C}	Change (%) (B-C)/C
Net sales	61,500	62,000	500	64,135	(2,135)	(3.3)
Sales of products	60,810	61,280	470	62,935	(1,655)	(2.6)
Renal disease and hemodialysis	21,390	21,700	310	25,276	(3,576)	(14.1)
Skin disease	9,190	9,190	_	9,905	(715)	(7.2)
Allergens	3,210	3,370	160	2,099	1,270	60.5
HIV infection	21,510	21,520	10	19,777	1,742	8.8
Other	5,510	5,500	(10)	5,877	(377)	(6.4)
Other sales	690	720	30	1,199	(479)	(40.0)
Cost of sales	31,600	31,700	100	31,293	406	1.3
Gross profit	29,900	30,300	400	32,841	(2,541)	(7.7)
SG&A	26,400	26,200	(200)	26,559	(359)	(1.4)
R&D expenses	4,700	4,400	(300)	4,608	(208)	(4.5)
Others	21,700	21,800	100	21,950	(150)	(0.7)
Operating income	3,500	4,100	600	6,281	(2,181)	(34.7)
Ordinary income	3,600	4,200	600	6,403	(2,203)	(34.4)
Net income	2,600	3,000	400	4,718	(1,718)	(36.4)

(Reference) Ratio to net sales

(%)	FY2018 previous forecast	FY2018 revised forecast	Change	FY2017	Change
	А	В	B-A	С	B-C
Cost of sales	51.4	51.1	(0.3)	48.8	2.3
SG&A	42.9	42.3	(0.6)	41.4	0.9
R&D expenses	7.6	7.1	(0.5)	7.2	(0.1)
Operating income	5.7	6.6	0.9	9.8	(3.2)
Ordinary income	5.9	6.8	0.9	10.0	(3.2)
Net income	4.2	4.8	0.6	7.4	(2.6)


(Cautionary Note Regarding FY2018 Forecasts)

In August 2018, JT signed a non-binding LOI for initiating a discussion with Gilead to terminate the license agreements for six anti-HIV drugs ("Viread Tablets" "Emtriva Capsules" "Truvada Combination Tablets" "Stribild Combination Tablets" "Genvoya Combination Tablets" and "Descovy Combination Tablets"). The anti-HIV drugs were developed by Gilead, and have been exclusively licensed to JT to develop and commercialize in Japan.

Torii and JT signed a non-binding LOI for initiating a discussion to terminate the license agreements by which JT grants Torii the exclusive rights to market the anti-HIV drugs in Japan.


The effect of the LOI on the business performance of Torii has not been incorporated in the forecasts for the FY2018. Torii will make a further announcement regarding this subject when appropriate.

[Factors in increase/decrease compared with the previous forecast for the FY2018]



Net sales (¥62,000 million : Increase ¥500 million)

Operating income (¥4,100 million : Increase ¥600 million)



R&D expenses : Decrease in co-development expenses (JTS-661, JTT-751) and clinical study expenses (TO-206)

Ordinary income (¥4,200 million : Increase ¥600 million)

Special remarks: None

Net income (¥3,000 million : Increase ¥400 million)

Special remarks: None

2 Sales of Products

illions of Yen)	FY2018 previous forecast	FY2018 revised forecast	Change	FY2017	Change	Change (%)
	A	B	B-A	С	B-C	(70) (B-C)/C
ales of Products	60,810	61,280	470	62,935	(1,655)	(2.6
Descovy	12,600	12,560	(40)	9,218	3,341	36.3
Antiviral agent for HIV [HIV infection]						
REMITCH	10,780	11,120	340	13,838	(2,718)	(19.6
Oral anti-pruritus agent [Renal disease and hemodialysis]						
Genvoya	7,330	7,370	40	6,325	1,044	16.5
Antiviral agent for HIV [HIV infection]						
Riona	6,860	6,760	(100)	6,245	514	8.2
Agent for hyperphosphatemia [Renal disease and hemodialysis]						
ANTEBATE 💥	5,620	5,600	(20)	6,282	(682)	(10.9
Topical corticosteroid [Skin disease]						
BIO-THREE	2,690	2,690	_	2,545	144	5.
Viable bacterial preparations [Other]	,	,		,		-
KAYEXALATE 💥	1,960	1,980	20	2,123	(143)	(6.
Agent for hyperkalemia [Renal disease and hemodialysis]						
CEDARTOLEN 💥	1,730	1,550	(180)	1,295	254	19.
Japanese cedar pollinosis (Allergen Immunothera [Allergens]	ару)					
LOCOID 💥	1,500	1,530	30	1,411	118	8.
Topical corticosteroid [Skin disease]						
ZEFNART	1,480	1,470	(10)	1,483	(13)	(0.
Topical antifungal agent [Skin disease]						
Truvada	1,400	1,420	20	3,941	(2,521)	(64.
Antiviral agent for HIV [HIV infection]						
FUTHAN X	1,100	1,150	50	2,047	(897)	(43.
Protease inhibitor [Renal disease and hemodialysis]	,	,		1 -	()	().
MITICURE X	860	1,050	190	461	588	127.
House dust mite allergy (Allergen Immunotherap [Allergens]	yy)					
Magsent	1,010	990	(20)	1,115	(125)	(11.
Tocolysis in threatened premature labor						
Eclampsia-suppressing and treatment [Other]						
URINORM X	690	690	-	1,020	(330)	(32.
Uricosuric agent [Renal disease and hemodialysis]						
Others	3,200	3,350	150	3,579	(229)	(6.

(References) Sales and ratio of in-house products

(Millions of Yen)		FY2018 previous forecast	FY2018 revised forecast	Change	FY2017	Change	Change (%)
		А	В	B-A	С	B-C	(B-C)/C
Sales of in-house produc	ts	15,310	15,510	200	16,323	(813)	(5.0)
Ratio of in-house product sales	(%)	25.2	25.3	0.1	25.9	(0.6)	-

③ Capital Expenditures

(Millions of Yen)	FY2018 previous forecast	FY2018 revised forecast	Change	FY2017	Change	Change (%)
	А	В	B-A	С	B-C	(B-C)/C
Capital expenditures	1,038	958	(80)	931	26	2.8
PP&E	813	749	(64)	714	34	4.9
Intangible assets	225	209	(16)	217	(8)	(4.0)

_		
	Descriptions of capita	l expenditures
	PP&E	: Investment mainly in manufacturing facilities aiming to maintain and improve productivity
	Intangible assets	: Investment in software aiming to streamline operations

④ Depreciation/Amortization

(Millions of Yen)	FY2018 previous forecast <i>A</i>	FY2018 revised forecast <i>B</i>	Change <i>B-A</i>	FY2017 C	Change <i>B-C</i>	Change (%) (B-C)/C
Depreciation and amortization of intangible assets	1,058	1,050	(8)	1,174	(124)	(10.6)
Amortization of long-term prepaid expenses	964	964	_	1,061	(97)	(9.2)

⑤ Dividends

		FY2018 previous forecast	FY2018 revised forecast	Change	FY2017	Change	Change (%)
		А	В	B-A	С	B-C	(B-C)/C
Dividends per share	(¥)	48	48	0	48	0	0.0
Dividends payout ratio	(%)	51.8	44.9	(6.9)	28.5	16.4	_

[Important notes on forward-looking statements]

The forecasts presented in this material are forward-looking statements. Reflecting assumptions based on information available on the date of publication, these statements are subject to inherent risks and uncertainties. Accordingly, unforeseen factors may cause actual results to differ materially from the projections contained herein.

Torii will not necessarily revise this material regardless of any new information, future events or other results.